Women and bone health

Maximizing the benefits of aromatase inhibitor therapy

Shou-Ching Tang

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Postmenopausal women with early breast cancer (EBC) are already at risk for bone loss, osteoporosis and fracture as they age because of declining estrogen levels. Adjuvant hormonal therapy with aromatase inhibitors (AIs; e.g. letrozole, anastrozole, exemestane) can exacerbate this risk. All three AIs appear to have similar effects on bone, increasing bone turnover and fracture risk in postmenopausal women with EBC. Risk factors for bone loss can be used to assess fracture risk and the need for ongoing assessment and/or treatment in postmenopausal women receiving AIs for EBC. The concomitant, up-front use of intravenous bisphosphonate therapy, such as zoledronic acid, in combination with AIs can inhibit bone loss. In addition, a strong body of evidence suggests an anticancer activity of bisphosphonate therapy with zoledronic acid in EBC in both the pre- and postmenopausal adjuvant setting. Zoledronic acid thus provides a therapeutic option for postmenopausal women with EBC who may be at higher risk for bone loss while on AIs, allowing more patients to receive treatment with effective adjuvant hormonal therapy to prevent recurrence.

Original languageEnglish (US)
Pages (from-to)13-26
Number of pages14
JournalOncology
Volume79
Issue number1-2
DOIs
StatePublished - Dec 1 2010

Fingerprint

Aromatase Inhibitors
Women's Health
Insurance Benefits
zoledronic acid
Bone and Bones
Breast Neoplasms
exemestane
letrozole
Diphosphonates
Therapeutics
Needs Assessment
Bone Remodeling
Bone Fractures
Osteoporosis
Estrogens
Recurrence

Keywords

  • Aromatase inhibitor
  • Bisphosphonates
  • Bone
  • Breast cancer
  • Osteoporosis
  • Postmenopausal women
  • Zoledronic acid

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Women and bone health : Maximizing the benefits of aromatase inhibitor therapy. / Tang, Shou-Ching.

In: Oncology, Vol. 79, No. 1-2, 01.12.2010, p. 13-26.

Research output: Contribution to journalReview article

Tang, Shou-Ching. / Women and bone health : Maximizing the benefits of aromatase inhibitor therapy. In: Oncology. 2010 ; Vol. 79, No. 1-2. pp. 13-26.
@article{5d679a7a4cd24bd0a833aeb86eb63028,
title = "Women and bone health: Maximizing the benefits of aromatase inhibitor therapy",
abstract = "Postmenopausal women with early breast cancer (EBC) are already at risk for bone loss, osteoporosis and fracture as they age because of declining estrogen levels. Adjuvant hormonal therapy with aromatase inhibitors (AIs; e.g. letrozole, anastrozole, exemestane) can exacerbate this risk. All three AIs appear to have similar effects on bone, increasing bone turnover and fracture risk in postmenopausal women with EBC. Risk factors for bone loss can be used to assess fracture risk and the need for ongoing assessment and/or treatment in postmenopausal women receiving AIs for EBC. The concomitant, up-front use of intravenous bisphosphonate therapy, such as zoledronic acid, in combination with AIs can inhibit bone loss. In addition, a strong body of evidence suggests an anticancer activity of bisphosphonate therapy with zoledronic acid in EBC in both the pre- and postmenopausal adjuvant setting. Zoledronic acid thus provides a therapeutic option for postmenopausal women with EBC who may be at higher risk for bone loss while on AIs, allowing more patients to receive treatment with effective adjuvant hormonal therapy to prevent recurrence.",
keywords = "Aromatase inhibitor, Bisphosphonates, Bone, Breast cancer, Osteoporosis, Postmenopausal women, Zoledronic acid",
author = "Shou-Ching Tang",
year = "2010",
month = "12",
day = "1",
doi = "10.1159/000314997",
language = "English (US)",
volume = "79",
pages = "13--26",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "1-2",

}

TY - JOUR

T1 - Women and bone health

T2 - Maximizing the benefits of aromatase inhibitor therapy

AU - Tang, Shou-Ching

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Postmenopausal women with early breast cancer (EBC) are already at risk for bone loss, osteoporosis and fracture as they age because of declining estrogen levels. Adjuvant hormonal therapy with aromatase inhibitors (AIs; e.g. letrozole, anastrozole, exemestane) can exacerbate this risk. All three AIs appear to have similar effects on bone, increasing bone turnover and fracture risk in postmenopausal women with EBC. Risk factors for bone loss can be used to assess fracture risk and the need for ongoing assessment and/or treatment in postmenopausal women receiving AIs for EBC. The concomitant, up-front use of intravenous bisphosphonate therapy, such as zoledronic acid, in combination with AIs can inhibit bone loss. In addition, a strong body of evidence suggests an anticancer activity of bisphosphonate therapy with zoledronic acid in EBC in both the pre- and postmenopausal adjuvant setting. Zoledronic acid thus provides a therapeutic option for postmenopausal women with EBC who may be at higher risk for bone loss while on AIs, allowing more patients to receive treatment with effective adjuvant hormonal therapy to prevent recurrence.

AB - Postmenopausal women with early breast cancer (EBC) are already at risk for bone loss, osteoporosis and fracture as they age because of declining estrogen levels. Adjuvant hormonal therapy with aromatase inhibitors (AIs; e.g. letrozole, anastrozole, exemestane) can exacerbate this risk. All three AIs appear to have similar effects on bone, increasing bone turnover and fracture risk in postmenopausal women with EBC. Risk factors for bone loss can be used to assess fracture risk and the need for ongoing assessment and/or treatment in postmenopausal women receiving AIs for EBC. The concomitant, up-front use of intravenous bisphosphonate therapy, such as zoledronic acid, in combination with AIs can inhibit bone loss. In addition, a strong body of evidence suggests an anticancer activity of bisphosphonate therapy with zoledronic acid in EBC in both the pre- and postmenopausal adjuvant setting. Zoledronic acid thus provides a therapeutic option for postmenopausal women with EBC who may be at higher risk for bone loss while on AIs, allowing more patients to receive treatment with effective adjuvant hormonal therapy to prevent recurrence.

KW - Aromatase inhibitor

KW - Bisphosphonates

KW - Bone

KW - Breast cancer

KW - Osteoporosis

KW - Postmenopausal women

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=78049366903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049366903&partnerID=8YFLogxK

U2 - 10.1159/000314997

DO - 10.1159/000314997

M3 - Review article

VL - 79

SP - 13

EP - 26

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 1-2

ER -